Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 11, 2022 at 05:23 pm EDT
Share
Genovate Biotechnology Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 108.46 million compared to TWD 100.28 million a year ago. Net income was TWD 3.2 million compared to net loss of TWD 2.91 million a year ago. Basic earnings per share from continuing operations was TWD 0.03 compared to basic loss per share from continuing operations of TWD 0.0294 a year ago. Diluted earnings per share from continuing operations was TWD 0.03 compared to diluted loss per share from continuing operations of TWD 0.0294 a year ago.
For the six months, sales was TWD 208.12 million compared to TWD 203.83 million a year ago. Net loss was TWD 6.19 million compared to net income of TWD 5.75 million a year ago. Basic loss per share from continuing operations was TWD 0.06 compared to basic earnings per share from continuing operations of TWD 0.049 a year ago. Diluted loss per share from continuing operations was TWD 0.06 compared to diluted earnings per share from continuing operations of TWD 0.049 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.